Research on TheraCryf PLC (TCF:LON) from Capital Access Group
TheraCryf has now completed the preclinical dose range finding studies for its Orexin-1 (Ox-1) blocker lead asset. That clears the way for the imminent start of the 28-day toxicology study which is the final major preclinical study prior to submission for regulatory approval in human clinical trials. TheraCryf is on track to complete all animal studies in 3Q26 and be ready to commence clinical trials in humans by the end of 2026, a key value inflection point, for which the company is fully funded. TheraCryf's valuation remains nugatory in relation to pharma deals for Central Nervous System compounds which typically attract upfront payments c5x TheraCryf's current market capitalisation for pre-clinical assets rising to c9x at clinical readiness.